SUCLG2 and cancer: However, SUCLG2 is mutated in 4.3% of patients with pheochromocytoma and paraganglioma, and its deletion results in aberrant respiration and elevated the succinate‐to‐fumarate ratio.[4] These observations demonstrate that SUCLG2 may play a pivotal role in cancer initiation and progression.